Combination of celecoxib and PD184161 exerts synergistic inhibitory effects on gallbladder cancer cell proliferation

Oncology Letters
Min DengJianchao Wang

Abstract

Cyclooxygenase-2 (COX-2) and extracellular signal-regulated kinase 1/2 (ERK1/2) may serve as potential targets in various types of cancer; however, the roles of these proteins in gallbladder carcinoma (GBC) have not been reported previously. In the present study, the expression levels of COX-2 and phospho (p)-ERK1/2 in GBC were examined and the biological activities of celecoxib and PD184161 (specific inhibitors of COX-2 and p-ERK1/2, respectively) on the proliferation, cell cycle and apoptosis of the GBC-SD and NOZ human GBC cell lines were evaluated by a series of in vitro and in vivo studies. COX-2 and p-ERK1/2 protein expression levels were found to be significantly elevated in GBC tissues as well as in GBC-SD and NOZ cells. Treatments with celecoxib and PD184161 significantly inhibited GBC-SD and NOZ cell growth in a concentration-dependent manner, and their combination produced a synergistic inhibitory effect. In addition, celecoxib and PD184161 significantly inhibited tumor growth in xenograft nude mice. Celecoxib treatment led to G1 arrest via the upregulation of p21 and p27 expression in GBC-SD and NOZ cells, whereas PD184161 did not affect cell cycle distribution. The combination of celecoxib and PD184161 was able to ...Continue Reading

References

Jan 1, 1979·International Journal of Radiation Oncology, Biology, Physics·G G Steel, M J Peckham
Mar 22, 2001·Radiographics : a Review Publication of the Radiological Society of North America, Inc·A D LevyC A Rohrmann
Feb 4, 2003·Brazilian Journal of Medical and Biological Research = Revista Brasileira De Pesquisas Médicas E Biológicas·S S SmailiR J Youle
Mar 5, 2004·British Journal of Cancer·S VicentL M Montuenga
Sep 2, 2004·Virchows Archiv : an International Journal of Pathology·Dominique WendumJean-François Fléjou
Dec 14, 2004·The Journal of Biological Chemistry·Sunil K Manna, Govindarajan T Ramesh
Sep 17, 2005·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Shahar Lev-AriNadir Arber
Mar 15, 2006·Neoplasia : an International Journal for Oncology Research·Patrick J KleinJudith S Sebolt-Leopold
May 25, 2006·Annals of Medicine·Michiaki Kohno, Jacques Pouyssegur
Jun 24, 2006·Journal of Cancer Research and Clinical Oncology·Artit JinawathChawalit Pairojkul
May 19, 2009·Journal of Experimental & Clinical Cancer Research : CR·Qinglong Li, Zhulin Yang
May 19, 2010·Gastroenterology Clinics of North America·Guy D Eslick
Jan 29, 2011·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Andrew X Zhu, Aram F Hezel
Aug 26, 2011·Drug Discovery Today·Giovanni BottegoniAndrea Cavalli
May 10, 2012·Gut and Liver·Laura M Stinton, Eldon A Shaffer
Dec 26, 2015·Advances in Experimental Medicine and Biology·Priyanga Wijesinghe, Aliccia Bollig-Fischer

❮ Previous
Next ❯

Citations

Dec 15, 2020·World Journal of Gastroenterology : WJG·Chong-Fei HuangWen-Bo Meng
Dec 19, 2020·Pharmaceuticals·Diana Xochiquetzal Robledo-CadenaSara Rodríguez-Enríquez

❮ Previous
Next ❯

Related Concepts

Related Feeds

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.